Requests that the FDA 1. Revise the guidance document(s) and, as necessary, associated regulations under 21 CFR Part 1271 for determining donor eligibility of Human Cells, Tissues, and Cellular and Tissue-Based Products (HCT/Ps), including reproductive tissues such as semen, to remove or substantially narrow geographic residency and travel deferrals related to variant Creutzfeldt-Jakob Disease | Federal Regulations · Congress.wiki

Nonrulemaking

FDA

Open for Comments

FDA-2026-P-7016

Requests that the FDA 1. Revise the guidance document(s) and, as necessary, associated regulations under 21 CFR Part 1271 for determining donor eligibility of Human Cells, Tissues, and Cellular and Tissue-Based Products (HCT/Ps), including reproductive tissues such as semen, to remove or substantially narrow geographic residency and travel deferrals related to variant Creutzfeldt-Jakob Disease

Documents

Comments

Description

Open

Key Dates

Comment Period OpensJun 24, 2026

Documents

Type	Title	Posted	Comments	Status
Other	Acknowledgement Letter from FDA DMB to Jack Weis	Jun 24, 2026	--

Keywords

CBER

Citizen Petition

Requests that the FDA:

1. Revise the guidance document(s) and, as

necessary, associated regulations under

21 CFR Part 1271 for determining

donor eligibility of Human Cells, Tissues, and

Cellular and Tissue-Based Products (HCT/Ps),

Data from Regulations.gov